Evidence map›Paper›PMID 41633699›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026

[Verbenalin ameliorates intestinal inflammation and colitis in a mouse model of Crohn's disease by inhibiting the PI3K-AKT pathway].

Linlin Huang, Wang Zheng, Jianguo Hu, Xue Song, Lu Tao, Zhijun Geng, Jing Li, Lugen Zuo, Sitang Ge

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Linlin HuangDepartment of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Wang ZhengDepartment of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Jianguo HuDepartment of Clinical Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Xue SongCentral Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Lu TaoCentral Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Zhijun GengCentral Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Jing LiDepartment of Clinical Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Lugen ZuoDepartment of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Sitang GeDepartment of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the therapeutic effect of verbenalin (VE) on Crohn's disease (CD)‑like colitis and the underlying molecular mechanism.

methodsFifty C57BL/6 mice were randomly divided into control group, TNBS group, and low-, medium-, and high-dose VE treatment groups (

resultsIn TNBS-treated mice, VE treatment significantly reduced DAI, histopathological scores, and spleen index, and mitigated weight loss, colon shortening and bacterial translocation. VE obviously lowered the expression of pro-inflammatory cytokines in colonic mucosa of the mice and the colon organoids, upregulated ZO-1 and claudin-1 expressions, and reduced bacterial translocation. VE significantly downregulated p-PI3K and p-AKT protein expressions, which was reversed by treatment with 740 Y-P.

conclusionsVE inhibits intestinal inflammation and protects intestinal barrier function in mice with CD-like colitis by modulating the PI3K-AKT signaling pathway.

Indexed as

ColitisCrohn DiseaseProto-Oncogene Proteins c-aktAnimalsColonDisease Models, AnimalInflammationIntestinal MucosaMaleMiceMice, Inbred C57BLPhosphatidylinositol 3-KinasesSignal TransductionPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktCrohn's diseaseinflammatory bowel diseaseintestinal barrierPI3K-AKTverbenalin

Identifiers

PMID41633699
PMCPMC12867607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.